Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 6 2015


Financial Report: Gilead

Published April 27, 2012

1Q Revenues: $2.3 billion (+19%)

1Q Earnings: $437.5 million (-32%)

Comments: Revenue growth in the quarter was driven by increased sales of Atripla and Truvada, and the launch of Complera/Eviplera. Atripla sales increased 19% to $887.6 million and Truvada sales were up 13% to $758.3 million. Sales of Complera/Eviplera more than doubled to $52.2 million compared to 4Q11. Sales of Viread increased 14% to $191.7 million. Royalty, contract and other revenues from collaborations were $74.1 million in the quarter, up 19%. Earnings included $193.9 million of acquisition-related compensation expense related to the Pharmasset acquisition.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On